智通财经APP讯，药捷安康-B(02617)发布公告，于2026年1月13日，公司与配售代理订立配售协议，配售代理将按尽力基准促使承配人按每股配售股份92.85港元的配售价购买210万股配售股份。配售股份相当于紧随完成后经配发及发行配售股份扩大后的已发行H股数目的约0.69%及已发行股份数目的约0.53%。每股配售股份92.85港元的配售价较股份于2026年1月13日在联交所所报的收市价每股H股113.20港元折让约17.98%。
预期配售事项最高所得款项总额及所得款项净额将分别约为1.95亿港元及1.90亿港元。按此基准，净发行价将约为每股配售股份90.54港元。公司拟按如下方式分配配售事项所得款项净额：配售事项所得款项净额的约60%用于为核心产品Tinengotinib在中国正在进行单药治疗胆管癌(CCA)的临床试验以及核心产品的其他适应症的研发提供资金;约30%用于其他产品的研发，包括TT-00973、TT-01488及其他分子;及约10%用于营运资金及一般企业用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.